Enliven Therapeutics, Inc. (ELVN) 10-Year Financial Performance & Capital Metrics

ELVN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.Show more

Revenue $0
EBITDA -$104M -25.2%
Net Income -$89M -24.4%
EPS (Diluted) -1.89 +6.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -32.04% +62.2%
ROIC -47.26%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 32.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-14.07%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.16%

ROCE

10Y Avg-68.43%

5Y Avg-34.98%

3Y Avg-44.24%

Latest-37.62%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.8B	105.95	706.33	14.76%	24.69%	25.55%	1.2%	0.01
TGTXTG Therapeutics, Inc.	4.69B	29.54	196.93	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.68B	28.73	2.47	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.9M	3.75	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	20.96M	1.02	-0.40	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	323.62M	14.77	-0.43			-94.52%		0.33
FATEFate Therapeutics, Inc.	124.58M	1.08	-0.66	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	131.65M	7.19	-0.76	-0.55%	-87.43%

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	33K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-33K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	1%	-	-	-	-
Operating Expenses+	8.9M	10.68M	24.08M	9.32M	24.76M	38.79M	83.53M	104.55M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	987K	2.44M	5.07M	1.08M	4.29M	7.77M	18.95M	23.78M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	7.92M	8.24M	19.01M	8.24M	20.47M	31.02M	64.57M	80.78M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-8.9M	-10.68M	-24.12M	-9.32M	-24.76M	-38.79M	-83.53M	-104.55M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.2%	-1.26%	0.61%	-1.66%	-0.57%	-1.15%	-0.25%
EBITDA+	221K	-11.34M	-24.08M	-9.27M	-24.65M	-38.58M	-83.23M	-104.24M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-52.3%	-1.12%	0.61%	-1.66%	-0.57%	-1.16%	-0.25%
D&A (Non-Cash Add-back)	0	-660K	33K	45K	115K	215K	297K	317K
EBIT	221K	-11.34M	-23.46M	-9.32M	-24.76M	-38.79M	-83.53M	-104.55M
Net Interest Income+	0	0	578K	483K	22K	1.13M	11.97M	14.89M
Interest Income	0	0	578K	483K	22K	1.13M	11.97M	14.89M
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	9.13M	-660K	653K	-9.65M	22K	1.13M	11.95M	15.76M
Pretax Income+	221K	-11.34M	-23.46M	-18.97M	-24.74M	-37.66M	-71.58M	-88.79M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	221K	0	0	0	0	0	0	232K
Effective Tax Rate %	-	1%	1%	1%	1%	1%	1%	1%
Net Income+	0	-11.34M	-23.46M	-18.97M	-24.74M	-37.66M	-71.58M	-89.02M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-	-1.07%	0.19%	-0.3%	-0.52%	-0.9%	-0.24%
Net Income (Continuing)	221K	-11.34M	-23.46M	-18.97M	-24.74M	-37.66M	-71.58M	-89.02M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.00	-2.62	-5.43	-4.31	-3.17	-6.03	-2.01	-1.89
EPS Growth %	-	-	-1.07%	0.21%	0.26%	-0.9%	0.67%	0.06%
EPS (Basic)	0.00	-2.62	-5.43	-4.31	-3.17	-6.03	-2.01	-1.89
Diluted Shares Outstanding	4.32M	4.32M	4.32M	4.39M	7.82M	6.25M	35.55M	47.07M
Basic Shares Outstanding	4.32M	4.32M	4.32M	4.39M	7.81M	6.25M	35.55M	47.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.22M	7.71M	30.62M	90.41M	110.67M	77.75M	266.15M	318.13M
Cash & Short-Term Investments	9.67M	7.38M	28.91M	88.22M	110.02M	75.54M	253.15M	313.44M
Cash Only	9.67M	7.38M	4.94M	47.7M	110.02M	75.54M	100.14M	124.12M
Short-Term Investments	0	0	23.97M	40.52M	0	0	153.01M	189.32M
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	552K	323K	1.72M	2.18M	0	2.22M	10.05M	4.69M
Total Non-Current Assets+	0	0	2.67M	437K	2.66M	5.54M	5.72M	7.63M
Property, Plant & Equipment	0	0	442K	349K	954K	1.52M	1.06M	458K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	88K	0	0	54K	0	0
Other Non-Current Assets	0	0	2.14M	88K	1.71M	3.98M	4.65M	7.17M
Total Assets+	10.22M	7.71M	33.3M	90.84M	113.33M	83.3M	271.87M	325.76M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.25%	3.32%	1.73%	0.25%	-0.26%	2.26%	0.2%
Total Current Liabilities+	826K	1.83M	4.2M	6.25M	5.75M	9.71M	25.89M	15.91M
Accounts Payable	431K	908K	1.66M	1.97M	2.52M	3.44M	532K	1.34M
Days Payables Outstanding	-	-	18.34K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K	0	0
Other Current Liabilities	196K	787K	1.74M	3.19M	233K	320K	10.36M	204K
Current Ratio	12.38x	4.21x	7.29x	14.47x	19.24x	8.00x	10.28x	19.99x
Quick Ratio	12.38x	4.21x	7.29x	14.47x	19.24x	8.00x	10.28x	19.99x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	660K	32.19M	184K	160K	714K	150.41M	67K	0
Long-Term Debt	660K	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	32.19M	184K	160K	714K	150.41M	67K	0
Total Liabilities	1.49M	1.83M	4.38M	6.41M	6.47M	160.12M	25.96M	15.91M
Total Debt+	660K	0	0	0	159K	323K	335K	0
Net Debt	-9.01M	-7.38M	-4.94M	-47.7M	-109.86M	-75.21M	-99.81M	-124.12M
Debt / Equity	-	-	-	-	0.00x	-	0.00x	-
Debt / EBITDA	2.99x	-	-	-	-	-	-	-
Net Debt / EBITDA	-40.77x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-15.53M	-26.32M	28.92M	84.44M	106.86M	-76.83M	245.91M	309.85M
Equity Growth %	-	-0.69%	2.1%	1.92%	0.27%	-1.72%	4.2%	0.26%
Book Value per Share	-3.60	-6.09	6.69	19.23	13.67	-12.29	6.92	6.58
Total Shareholders' Equity	-15.53M	-26.32M	-48.85M	84.44M	106.86M	-76.83M	245.91M	309.85M
Common Stock	4K	4K	4K	18K	1K	1K	41K	49K
Retained Earnings	-19.95M	-31.29M	-54.75M	-96.11M	-45.2M	-82.86M	-154.45M	-243.47M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	32K	4K	0	-149.75K	141K	55K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.79M	-8.78M	-21.88M	-8.53M	-19.13M	-32.08M	-61.27M	-73.19M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0%	-1.49%	0.61%	-1.24%	-0.68%	-0.91%	-0.19%
Net Income	0	-11.34M	-23.46M	-18.97M	-24.74M	-37.66M	-71.58M	-89.02M
Depreciation & Amortization	0	0	33K	45K	115K	215K	297K	317K
Stock-Based Compensation	0	555K	899K	130K	1.92M	3.19M	12.91M	20.17M
Deferred Taxes	0	0	-215K	0	-3.81M	0	0	0
Other Non-Cash Items	-7.93M	848K	196K	9.68M	3.81M	1.74M	-4.3M	-118K
Working Capital Changes	-188K	1.24M	673K	583K	3.57M	438K	1.4M	-4.54M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	-666K	477K	750K	291K	1.73M	411K	-2.25M	810K
Cash from Investing+	0	0	-24.06M	-461K	-191K	-612K	-148.41M	-36M
Capital Expenditures	0	0	-140K	-461K	-191K	-612K	-149K	-44K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	16.7M	1.62M	-41.88M	0	873K
Cash from Financing+	11M	6.49M	43.58M	130.51M	-1.02M	-1.8M	234.29M	133.16M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	11M	6.49M	0	33.63M	0	-566K	73.08M	93.98M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.79M	-8.78M	-22.02M	-8.99M	-19.32M	-32.69M	-61.42M	-73.24M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0%	-1.51%	0.59%	-1.15%	-0.69%	-0.88%	-0.19%
FCF per Share	-2.03	-2.03	-5.10	-2.05	-2.47	-5.23	-1.73	-1.56
FCF Conversion (FCF/Net Income)	-	0.77x	0.93x	0.45x	0.77x	0.85x	0.86x	0.82x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	232K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-1804.85%	-33.46%	-25.87%	-250.77%	-84.67%	-32.04%
Return on Invested Capital (ROIC)	-	-	-	-23.02%	-110.11%	-	-	-47.26%
Debt / Equity	-	-	-	-	0.00x	-	0.00x	-
FCF Conversion	-	0.77x	0.93x	0.45x	0.77x	0.85x	0.86x	0.82x

Frequently Asked Questions

Growth & Financials

Enliven Therapeutics, Inc. (ELVN) grew revenue by 0.0% over the past year. Growth has been modest.

Enliven Therapeutics, Inc. (ELVN) reported a net loss of $97.2M for fiscal year 2024.

Dividend & Returns

Enliven Therapeutics, Inc. (ELVN) has a return on equity (ROE) of -32.0%. Negative ROE indicates the company is unprofitable.

Enliven Therapeutics, Inc. (ELVN) had negative free cash flow of $71.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener